Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
44.7
% (year-on-year decline in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPNet Sales66,887¥ millionYear on year +4.7%Progress 49.2%
Operating profit710¥ millionYear on year -44.7%Progress 23.7%
Ordinary income607¥ millionYear on year -50.0%Progress 22.5%
Net income attributable to owners of the parent57¥ millionYear on year -87.2%Progress 5.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥1.98
Financial position at period-end
Total assets76,457¥ million
of which net assets 17,335 ¥ millionEquity ratio 22.5%vs. prior year-end +0.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+3,211
Investment-1,578
Financials-3,048
Net change-1,415
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥6,327 million
Segment revenueRegional Pharmacy Network Business ¥64,930 million (YoY +5.7%), Rental and Facilities-Related Business ¥1,539 million (YoY +5.7%), Other Business ¥798 million (YoY -40.0%)
Segment profitRegional Pharmacy Network Business ¥2,205 million (YoY -13.8%), Rental and Facilities-Related Business ¥45 million (YoY +9.4%), Other Business ¥-46 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥136,000 million (YoY +2.9%)
Operating profit¥3,000 million (YoY -9.4%)
Ordinary income¥2,700 million (YoY -15.4%)
Net income¥1,000 million (YoY -6.6%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast12 Yen → 12 Yen（0.0%）
Factors Behind Changes in Business Performance
Although the Company worked to expand the number of supported locations, higher pharmaceutical procurement prices, increased personnel expenses, and higher system-related costs associated with integrating the customer management platform and improving existing systems, among other factors, resulted in higher net sales but lower operating profit, ordinary profit, and interim net income attributable to owners of the parent.
Disclosure regarding the going concern assumption
None ("There are no applicable matters")
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNew Number of companies 1 / Company name (株)グランツリー / Excluded Number of companies 2 / Company name (株)クライマー, (株)グランツリー
Impairment loss¥60 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥7 million, Gain on transfer of business ¥0 million / Extraordinary loss Loss on sale of non-current assets ¥0 million, Loss on disposal of fixed assets ¥4 million, Impairment Losses ¥60 million, Loss on closure of stores ¥14 million, Loss on transfer of business ¥7 million, Other ¥3 million
Depreciation and amortization¥1,227 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End30,642,600
Treasury Shares at Period-End1,414,124
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥66,887 million (YoY +4.7%) |
| Operating profit | ¥710 million (YoY -44.7%) |
| Ordinary income | ¥607 million (YoY -50.0%) |
| Profit attributable to owners of the parent | ¥57 million (YoY -87.2%) |
| Net income per share | ¥1.98 |
| Equity ratio | End of the current fiscal period 22.5 % / End of previous period 21.6 % |
| Total assets | ¥76,457 million |
| Net assets | ¥17,335 million |
| Cash flows from operating activities | ¥3,211 million |
| Cash flows from investing activities | ¥-1,578 million |
| Cash flows from financing activities | ¥-3,048 million |
| Cash and cash equivalents at end of period | ¥6,327 million |
| Full-year earnings forecast | Net Sales ¥136,000 million (YoY +2.9%) / Operating profit ¥3,000 million (YoY -9.4%) / Ordinary income ¥2,700 million (YoY -15.4%) / Net income ¥1,000 million (YoY -6.6%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | 12 Yen → 12 Yen（0.0%） |
| Segment revenue | Regional Pharmacy Network Business ¥64,930 million (YoY +5.7%), Rental and Facilities-Related Business ¥1,539 million (YoY +5.7%), Other Business ¥798 million (YoY -40.0%) |
| Segment profit | Regional Pharmacy Network Business ¥2,205 million (YoY -13.8%), Rental and Facilities-Related Business ¥45 million (YoY +9.4%), Other Business ¥-46 million |
| Depreciation and amortization | ¥1,227 million |
| Impairment loss | ¥60 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥7 million, Gain on transfer of business ¥0 million / Extraordinary loss Loss on sale of non-current assets ¥0 million, Loss on disposal of fixed assets ¥4 million, Impairment Losses ¥60 million, Loss on closure of stores ¥14 million, Loss on transfer of business ¥7 million, Other ¥3 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 1 / Company name (株)グランツリー / Excluded Number of companies 2 / Company name (株)クライマー, (株)グランツリー |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 30,642,600 |
| Treasury Shares at Period-End | 1,414,124 |
| Factors Behind Changes in Business Performance | Although the Company worked to expand the number of supported locations, higher pharmaceutical procurement prices, increased personnel expenses, and higher system-related costs associated with integrating the customer management platform and improving existing systems, among other factors, resulted in higher net sales but lower operating profit, ordinary profit, and interim net income attributable to owners of the parent. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the Company worked to expand the number of supported locations, higher pharmaceutical procurement prices, increased personnel expenses, and higher system-related costs associated with integrating the customer management platform and improving existing systems weighed on profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.